Michael Gould to Radiopharmaceuticals
This is a "connection" page, showing publications Michael Gould has written about Radiopharmaceuticals.
Connection Strength
0.796
-
Positron emission tomography 18F-fluorodeoxyglucose uptake and prognosis in patients with surgically treated, stage I non-small cell lung cancer: a systematic review. J Thorac Oncol. 2009 Dec; 4(12):1473-9.
Score: 0.359
-
The use and misuse of positron emission tomography in lung cancer evaluation. Clin Chest Med. 2011 Dec; 32(4):749-62.
Score: 0.103
-
Disparities in lung cancer staging with positron emission tomography in the Cancer Care Outcomes Research and Surveillance (CanCORS) study. J Thorac Oncol. 2011 May; 6(5):875-83.
Score: 0.099
-
Test performance of positron emission tomography and computed tomography for mediastinal staging in patients with non-small-cell lung cancer: a meta-analysis. Ann Intern Med. 2003 Dec 02; 139(11):879-92.
Score: 0.059
-
Cost-effectiveness of alternative management strategies for patients with solitary pulmonary nodules. Ann Intern Med. 2003 May 06; 138(9):724-35.
Score: 0.057
-
Accuracy of positron emission tomography for diagnosis of pulmonary nodules and mass lesions: a meta-analysis. JAMA. 2001 Feb 21; 285(7):914-24.
Score: 0.049
-
Use of [(18)F]Fluoro-2-deoxy-d-glucose Positron Emission Tomographic Imaging in the National Lung Screening Trial. Chest. 2016 09; 150(3):621-30.
Score: 0.035
-
A comparison of the diagnostic accuracy of 18F-FDG PET and CT in the characterization of solitary pulmonary nodules. J Nucl Med. 2008 Feb; 49(2):179-85.
Score: 0.020
-
The cost of positron emission tomography in six United States Veterans Affairs hospitals and two academic medical centers. AJR Am J Roentgenol. 2003 Aug; 181(2):359-65.
Score: 0.014